

HR 4879

Research for All Act of 2014

Congress: 113 (2013–2015, Ended)

Chamber: House

Policy Area: Health

Introduced: Jun 17, 2014

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jun 20, 2014)

Official Text: <https://www.congress.gov/bill/113th-congress/house-bill/4879>

Sponsor

Name: Rep. Cooper, Jim [D-TN-5]

Party: Democratic • **State:** TN • **Chamber:** House

Cosponsors (13 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Lummis, Cynthia M. [R-WY-At Large]	R · WY		Jun 17, 2014
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Jun 23, 2014
Rep. Kaptur, Marcy [D-OH-9]	D · OH		Jun 23, 2014
Rep. Enyart, William L. [D-IL-12]	D · IL		Jun 25, 2014
Rep. Holt, Rush [D-NJ-12]	D · NJ		Jun 25, 2014
Rep. Slaughter, Louise McIntosh [D-NY-25]	D · NY		Jun 25, 2014
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Jul 3, 2014
Rep. Moran, James P. [D-VA-8]	D · VA		Sep 8, 2014
Rep. Ellison, Keith [D-MN-5]	D · MN		Sep 17, 2014
Rep. Ribble, Reid J. [R-WI-8]	R · WI		Sep 17, 2014
Rep. Grijalva, Raúl M. [D-AZ-3]	D · AZ		Nov 13, 2014
Rep. Hastings, Alcee L. [D-FL-20]	D · FL		Dec 4, 2014
Rep. Waters, Maxine [D-CA-43]	D · CA		Dec 11, 2014

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 20, 2014

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Research for All Act of 2014 - Directs the Food and Drug Administration (FDA) to review and develop policies to ensure that the design and size of clinical trials for products granted expedited approval to treat a serious or life-threatening disease or condition are sufficient to determine the safety and effectiveness of the products for men and women using subgroup analysis.

Amends the Federal Food, Drug, and Cosmetic Act to require FDA, at the request of the sponsor of a new drug, to facilitate the development and expedite its review if the drug is:

- intended to avoid serious adverse events or to treat a serious or life-threatening disease or condition,
- intended for safer or more effective treatment for either men or women than a currently available product approved to treat the general population or the other sex, and
- supported by results of clinical trials that include and separately examine outcomes for men and women.

Amends the Public Health Service Act to require the Director of the National Institutes of Health (NIH) to determine when it is appropriate for projects of basic research involving cells, tissues, or animals to include both male and female cells, tissues, or animals. Requires, in such cases, disaggregation of results according to sex. Provides guidelines for ensuring that sex differences are examined and analyzed.

Authorizes the Secretary of Health and Human Services (HHS) to support the continued operation and expansion of Special Centers of Research on Sex Differences.

Requires the Comptroller General (GAO) to provide to Congress updated versions of the reports entitled “Women's Health: NIH Has Increased Its Efforts To Include Women in Research” and “Women's Health: Women Sufficiently Represented in New Drug Testing, But FDA Oversight Needs Improvement,” including in the reports examination of:

- the inclusion of women, female animals, and female-derived cells and tissues in federally funded research over the past decade;
- federal reporting and analysis of subgroup information and the translation of differences to the medical community and patients;
- the effect of inclusion rates in research on the quality of women's health care; and
- current efforts within government agencies to encourage the sharing of research data on sex differences and mechanisms to improve such sharing.

Actions Timeline

- **Jun 20, 2014:** Referred to the Subcommittee on Health.
- **Jun 17, 2014:** Introduced in House
- **Jun 17, 2014:** Referred to the House Committee on Energy and Commerce.